Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Licensing Agreements
Molecular Insight Pharmaceuticals acquires malignant melanoma compound from Bayer Schering
February 27th, 2007
Molecular Insight Pharmaceuticals, Inc. announced that it has entered into a worldwide, exclusive licensing agreement with Bayer Schering Pharma to acquire ZK-BA, a compound in development for the treatment of malignant melanoma. ZK-BA (Solazed) joins Azedra (Ultratrace iobenguane I 131) and Onalta (an yttrium-90 radiolabeled somatostatin peptide analog) in Molecular Insight's portfolio of targeted radiotherapeutic product candidates. Under terms of the agreement, Molecular Insight Pharmaceuticals will pay Bayer Schering Pharma a licensing fee and additional payments upon completion of certain regulatory milestones, with royalties payable to Schering...
Source: Cancer Weekly (2007-02-27)
|
